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ABSTRACT
Exosomes are a class of nanovesicles formed and released through the late endosomal compartment and
represent an important mode of intercellular communication. The ability of anticancer chemotherapy to
enhance the immunogenic potential of malignant cells mainly relies on the establishment of the
immunogenic cell death (ICD) and the release of damage-associated molecular patterns (DAMPs). Here,
we investigated whether genotoxic stress could promote the release of exosomes from multiple myeloma
(MM) cells and studied the immunomodulatory properties they exert on NK cells, a major component of
the antitumor immune response playing a key role in the immunosurveillance of MM. Our findings show
that melphalan, a genotoxic agent used in MM therapy, significantly induces an increased exosome
release from MM cells. MM cell-derived exosomes are capable of stimulating IFNg production, but not the
cytotoxic activity of NK cells through a mechanism based on the activation of NF-kB pathway in a TLR2/
HSP70-dependent manner. Interestingly, HSP70C exosomes are primarily found in the bone marrow (BM)
of MM patients suggesting that they might have a crucial immunomodulatory action in the tumor
microenvironment. We also provide evidence that the CD56high NK cell subset is more responsive to
exosome-induced IFNg production mediated by TLR2 engagement. All together, these findings suggest a
novel mechanism of synergism between chemotherapy and antitumor innate immune responses based
on the drug-promotion of nanovesicles exposing DAMPs for innate receptors.
Abbreviations: BM, bone marrow; DAMP, damage-associated molecular pattern; DLS, dynamic light scattering; ER,
endoplasmic reticulum; HMGB1, high-mobility group box 1; HSP, heat shock protein; ICD, immunogenic cell death;
IFN, interferon; MDSC, myeloid-derived suppressor cells; MEL, melphalan; MM, multiple myeloma; NF-kB, nuclear
factor-kB; NK, natural killer; PAMP, pathogen-associated molecular pattern; PB, peripheral blood; PC, plasma cell;
TLR, toll-like receptor
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Introduction
Developmental patterns, tissue homeostasis and immunological
responses are regulated by cellular cross-talk. Traditionally, cells
communicate with each other through direct cell–cell contact
and/or soluble factors. However, recent work has pointed out as
novel and crucial regulators of cellular cross-talk, the exosomes,
endosome-derived nanovesicles, which are released in the extra-
cellular environment and are subsequently uptaken by homo-
and/or hetero-typic cells.1,2 In this context, a fast developing
field is that focusing on how exosomes released by cancer cells in
the tumor microenvironment are uptaken by different immune
cell types, thereby modulating antitumor immune response and
affecting tumor progression.3,4
Natural killer (NK) cells are innate immune effectors that
play a pivotal role in tumor immunosurveillance by exerting
direct cytotoxic effects as well as producing a variety of cyto-
kines. NK cell activation is tightly regulated by a fine balance
between activating and inhibitory signals. Recognition of
altered self on tumor cells triggers non-MHC class-I-restricted
activating receptors.5 In addition, NK cells can directly recog-
nize several molecular patterns of ligands (i.e., pathogen-associ-
ated molecular patterns, PAMPs and damage-associated
molecular patterns, DAMPs) through receptors belonging to
the toll-like receptor family (TLRs).6 Human NK cells can be
subdivided into various subsets based on the relative expression
CONTACT Angela Santoni angela.santoni@uniroma1.it; Alessandra Zingoni alessandra.zingoni@uniroma1.it Department of Molecular Medicine, University
of Rome “Sapienza” - Viale Regina Elena 291, 00161 - Rome, Italy.
Supplemental data for this article can be accessed on the publisher’s website.
*These authors equally contributed to the work.
© 2017 Taylor & Francis Group, LLC
ONCOIMMUNOLOGY
2017, VOL. 6, NO. 3, e1279372 (15 pages)
http://dx.doi.org/10.1080/2162402X.2017.1279372
of CD16 and CD56. In particular, the CD56low CD16high popu-
lation is predominant in peripheral blood (PB), whereas tissue
resident NK cells are primarily CD56high. The latter are more
efficient producers of cytokines endowed with immunoregula-
tory properties, but they can also become cytotoxic upon
appropriate activation and have been implicated to different
disease states including cancer.7
Multiple myeloma (MM) is a clonal B-cell malignancy char-
acterized by the expansion of plasma cells (PCs) in the bone
marrow (BM). NK cells have long been considered essential in
the control of MM progression, because they undergo expan-
sion and activation during the early stages of disease and have
the ability to recognize and kill MM cells.8 This notion has
spurred great interest in developing strategies aimed at stimu-
lating NK cell-mediated functions for MM immunotherapy.9-12
The ability of anticancer chemotherapy and radiotherapy to
enhance the immunogenic potential of malignant cells mainly
relies on the establishment of immunogenic cell death (ICD)
and release of DAMPs, including heat shock proteins (HSPs),
high-mobility group box 1 proteins (HMGB1), ATP and the
endoplasmic reticulum (ER) chaperone calreticulin.13,14 In this
context, both HSP70 and HMGB1 appear to exert an immu-
nostimulatory activity by promoting DC maturation through
TLR4, which, in turn, leads to the induction of antigen-specific
T cell-mediated antitumor immune responses.15,16 In this
regard, several studies highlight the importance of TLRs in the
modulation of innate immune response in anticancer immu-
nity.17,18 More recently, low doses of chemotherapeutic drugs
have been shown to induce immunogenic senescence and stim-
ulate NK cell-mediated recognition and clearance of drug-
treated tumor cells via the upregulation of NKG2D and
DNAM-1 activating ligands on the surface of cancer cells.19-22
An outstanding question concerns the role of tumor-derived
exosomes (Tex) on the modulation of NK cell-mediated func-
tions. The available evidence points to the molecular composi-
tion of the exosome cargo as a major determinant of the
immunoregulatory activity of Tex on NK cells pointing to a
prevailing, although not exclusive, inhibitory role.23 Accord-
ingly, exosomes carrying TGF-b and/or ligands for the activat-
ing receptor NKG2D have been described to negatively affect
NK cell functions.24-30 In contrast, exosomes displaying high
levels of HSP70 were reported to enhance NK cell migration
and cytotoxicity through a still unknown mechanism.31,32 Stim-
ulation of NK cell activity by Tex was also shown to be depen-
dent on NKp30 ligand BAT3 expressed on the exosome
surface.33,34
We endeavored to address whether exosomes released by
MM cells exposed to sublethal doses of melphalan (MEL), a
drug currently used in the clinical management of MM
patients, affect NK cell effector functions. Herein, we show that
MM-derived exosomes are capable of stimulating the produc-
tion of IFNg by NK cells through a mechanism based on the
activation of the NF-kB pathway in a TLR-2/HSP70-dependent
manner. We also provide evidence that the CD56high subset is
more responsive to exosome stimulation. Our findings suggest
a novel mechanism whereby a chemotherapeutic drug can
enhance antitumor innate immune responses via the release of
nanovesicles carrying DAMPs/HSP70 capable of triggering the
activation of innate receptor/TLR2 expressed by NK cells.
Results
Structural and biochemical characterization of exosomes
derived from multiple myeloma cells in steady-state
conditions and upon MEL treatment
To isolate and characterize exosome release by MM cells, we
used an established exosome isolation protocol that exploits
their differential sedimentation properties.35 Exosomes were
isolated from the conditioned media of ARK and SKO-007(J3)
MM cell lines either under steady-state conditions or upon
treatment with sublethal doses of MEL. Dynamic light scatter-
ing (DLS) methodology was used to evaluate exosome size dis-
tribution and quantify their number (Figs. S1A–D). Our results
show that exosomal preparations from both cell lines contain
vesicles whose diameter ranges from 60 to 130 nm, thus match-
ing the reported size of typical exosomes. In addition, drug
treatment increased the amount of released exosomes without
affecting their size distribution (Fig. 1A). Remarkably, the
higher number of exosomes released by drug-treated cells
yielded an increased amount of total proteins recovered from
the exosomal samples (Fig. 1B), implying constant loading of
cargo into exosomes. Interestingly, although at the steady-state
ARK cells secreted more nanovesicles when compared with
SKO-007(J3) cells, the relative increase of exosome production
in response to MEL treatment was similar in the two MM cell
lines (Figs. 1C and D).
We confirmed through ultrastructural analysis that our
MM-purified exosome preparations contained nano-sized cup-
shaped vesicles (Fig. 2A). In addition, immunogold labeling
showed the expression of specific exosome markers such as
CD81 and Tsg101 on the outer layer of MM vesicles (Fig. 2B).
In accordance with the results obtained by DLS, the ultrastruc-
tural analysis did not reveal any relevant morphological differ-
ence among exosomes purified from control and drug-treated
cells (Fig. S2). In addition, we readily detected canonical exo-
some markers such as Tsg101, CD63, MHC I and HSP70 by
Western blot analysis. Importantly, calreticulin, which is exclu-
sively associated to ER, was not detected in the exosome prepa-
rations (Fig. 2C). Again, a similar marker profile was found in
exosomes derived from control and MEL-treated cells. CD63
expression on the surface of exosomes was also evaluated by
immunofluorescence and flow cytometric (FACS) analysis
(Fig. 2D).
All together, these data indicate that MM cells secrete exo-
somes and MEL treatment increases their release without
affecting their size or marker content.
MM-derived exosomes are uptaken by NK cells and
stimulate CD69 expression
To investigate the effects of MM-derived exosomes on NK cell-
mediated functions, we first explored whether these nanove-
sicles could be uptaken by NK cells. Exosomes labeled with the
fluorescent PKH26 dye were incubated for different length of
time with highly purified NK cells with or without IL-15 sup-
plementation. As shown in Fig. 3A, both resting and IL-15-acti-
vated NK cells were labeled by PKH6, with a peak of
fluorescence being detected at 3 h. To directly demonstrate that
exosomes were internalized and not just bound to the cell
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Figure 1. Melphalan-treated MM cells release a higher amount of exosomes. (A) MM cells were cultured for 48 h in the presence or not of MEL, and then exosomes were
isolated from the conditioned media. Size distribution of SKO-007(J3)- and ARK-derived exosomes was analyzed through DLS. A representative experiment out of three is
shown. (B) The number of exosomes/cell was calculated through the DLS (details can be found in Fig. S1). In parallel, the amount of total proteins recovered from exoso-
mal preparations derived from 106 cells was evaluated by BPA. The mean values of three (for SKO-007(J3)) or four (for ARK) independent experiments § SEM is shown.
(C) Data are expressed as fold increase of the number of particles/cell obtained from MEL-treated MM cells divided by the number of particles/cell of the untreated group.
The mean of three (for SKO-007(J3)) or four (for ARK) independent experiments § SEM is shown. (D) Data are expressed as fold increase of the mg of exosomal proteins/
106 cells values obtained from MEL treated MM cells divided by mg/106 cells of the untreated group. The mean of nine (for SKO-007(J3)) or six (for ARK) independent
experiments § SEM is shown.
Figure 2. Characterization of MM cell-derived exosomes. (A) Electron microscope analysis of exosomes morphology and size. A representative picture of SKO-007(J3)-
derived exosomes is shown. (B) Immune-gold labeling for Tsg101 and CD81 of SKO-007(J3)-derived exosomes. (C) Western blot analysis was performed on lysates derived
from exosome fractions or from cell pellet, using anti-Hsp70, anti-MHC I, anti-Tsg101, anti-CD63 and anti-calreticulin antibodies. (D) Visualization of CD63-conjugated
beads coated with exosomes by immunofluorescence and FACS analysis (upper panel). CD63 expression on the surface of exosomes was assessed after overnight incuba-
tion of exosomes with beads, exosomes were stained with anti-CD63 mAb (thin histograms) or control isotypic Ig (filled histograms) (bottom panel).
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surface, exosome–NK cell conjugates were treated with trypsin
before FACS analysis. We found that trypsin treatment reduced
the percentage of fluorescent cells marginally, thus supporting
the notion that the majority of PKH26-labeled exosomes were
distributed intracellularly (Fig. 3B). In addition, when NK cells
were incubated with an excess of unlabeled exosomes, we could
not detect PKH26C cells, strongly suggesting that NK cells were
labeled by PKH26 as a consequence of exosome uptake
(Fig. 3B). Fluorescence microscopy imaging of NK cells incu-
bated for 3 h with PKH26-labeled exosomes further confirmed
exosome internalization (Fig. 3C). We verified that CD56high
and CD56low NK cell subsets had a similar capability to uptake
exosomes (Fig. 3D). Next, we assessed the mechanism by which
exosomes are internalized into human primary NK cells. The
uptake of exosomes was strongly impaired when cells were
assayed either in presence of EDTA (Fig. 3E) or at 4C (not
shown), suggesting that exosome uptake is an energy-depen-
dent process reliant on tensile forces generated by the actin
cytoskeleton. In addition, exosome uptake was markedly
reduced by nystatin and dynasore, which implies its depen-
dence on endocytic route/s requiring caveolae/raft integrity
and dynamin function36 (Fig. 3E). EIPA caused a minor reduc-
tion of exosome uptake, pointing to macropynocytosis as an
additional, albeit marginally relevant, route of exosome inter-
nalization in NK cells.
To analyze whether exosomes could affect NK cell activa-
tion, we incubated primary PB NK cells with different amounts
of exosomes and evaluated expression of the activation marker
CD69. Interestingly, CD69 was induced on exosome-treated
NK cells in a dose-dependent manner (Fig. 3F). Similar effects
were observed using exosomes released from ARK or SKO-007
(J3) MM cells, with no significant differences between
Figure 3. MM cell-derived exosomes are uptaken by primary NK cells and induce CD69 expression. (A) SKO-007(J3)-derived exosomes were labeled with the red fluores-
cent dye PKH26. Primary peripheral blood human NK cells were incubated for different times with 20 mg/mL of PKH26-labeled exosomes with or without IL-15 (50 ng/
mL). The fluorescence of internalized exosomes was evaluated by immunofluorescence and FACS analysis and measured as the percentage of PKH26C cells. One represen-
tative experiment is shown. (B) NK cells were cultured for 3 h in the presence of PKH26-labeled exosomes and IL-15 as described in panel (A), or with a combination of
PKH26-labeled exosomes and trypsin, or PKH26-labeled and unlabeled exosomes at 1:3 ratio. The mean of three independent experiments § SEM is shown. (C) NK cells
were incubated for 3 h with PKH26-labeled exosomes (20 mg/mL), washed and plated on poly-L-lysine-coated multichamber glass plates and fixed. Images were acquired
using an ApoTome Observer Z.1 microscope with a 60x/1.4 NA Plan-Neofluar oil immersion objective. Upper panels: Representative images of single cells are shown as
maximum intensity projection (3 Z sections with 0.2 mm spacing). Lower panels: Differential interference contrast overlay the fluorescence images were also shown. Bar
represents 5 mm. (D) NK cells were incubated for 3 h with PKH26-labeled exosomes (20 mg/mL), anti-CD56APC was added the last 20 min. Cells were washed and the
fluorescence of internalized exosomes was evaluated by immunofluorescence and FACS analysis and measured as the percentage of PKH26C cells by gating on CD56low
and CD56high subsets. The mean of four experiments is shown. (E) NK cells were pre-treated for 1 h with EDTA (2 mM), EIPA (50 mM), dynasore (50 mM), nystatin (40 mg/
mL) and then incubated for 3 h with PKH26-labeled exosomes (20 mg/mL), the fluorescence of internalized exosomes was evaluated by immunofluorescence and FACS
analysis and measured as the percentage of PKH26C cells. Data expressed as the percentage of uptake were referred to the untreated cells considered as 100%. Values
reported represent the mean of three independent experiments § SEM. (F) NK cells were incubated for 48 h with different amounts of SKO-007(J3)-derived exosomes as
indicated. CD69 expression was evaluated by immunofluorescence and FACS analysis. Numbers in each histogram represent the percentage of CD69C cells. A representa-
tive experiment is shown. (G) NK cells were incubated with 20 mg/mL of SKO-007(J3) and ARK–derived exosomes as described in panel (F). Where indicated, exosomes
were prepared from MEL-treated MM cells (exo MEL). Data are represented as the mean values of the percentage of CD69C NK cells of four (for SKO-007(J3)-derived exo-
somes) or five (for ARK-derived exosomes) independent experiments § SEM.
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exosomes derived from untreated or MEL-treated MM cells
(Fig. 3G).
MM-derived exosomes stimulate IFNg production through
a mechanism mediated by nuclear factor (NF)-kB signaling
pathway
Next, we investigated whether MM cell-derived exosomes could
affect NK cell-mediated effector functions. To this aim, NK cell
degranulation, cytotoxicity and cytokine production were mea-
sured following incubation with exosomes. We found that treat-
ment of NK cells with exosomes affected neither degranulation (as
determined by CD107a surface expression) (Figs. 4A and B) nor
cytotoxic activity (Figs. 4C and D) toward co-cultured K562 cells.
In contrast, a significant increase in the production of IFNg and
some chemokines, including CXCL8/IL-8, CCL5/Rantes and
CCL4/MIP-1bwas observed upon exosome treatment (Fig. 4E).
We then examine the molecular mechanism/s through which
the MM-derived exosomes could induce IFNg production by NK
cells. We verified that exosome-mediated IFNg production by NK
cells was associated to increased expression of IFNG mRNA
(Fig. 5A); notably, neither exosomes derived from non-malignant
cells (such as primary fibroblasts or PBMCs) nor synthetic lipo-
somes exerted a stimulatory effect (Fig. S3).
To investigate possible signaling pathways involved in exosome-
induced INFg production, we focused our attention on NF-kB,
since this transcription factor was shown to be involved in the tran-
scription of several cytokines, including IFNg.37 Our results show
that exosomes caused an increase of p65 phosphorylation, a major
activating component of NF-kB signaling, leaving p65 total levels
unchanged (Fig. 5B). To further support the possible involvement
of NF-kB in the exosome-induced IFNg production, NK cells were
pre-treated with SN50, a cell permeable peptide that inhibits trans-
location of the NF-kB active complex into the nucleus, and then
incubated with exosomes. As shown in Fig. 5C, SN50 treatment
inhibited exosome-induced IFNg production. Importantly, this
compound did not affect exosome uptake (data not shown). More-
over, as shown in the EMSA assay, MM-derived exosomes
enhanced specific binding to a IFNg/NF-kB site previously identi-
fied within the promoter region of this gene37 confirming the
involvement of this pathway in the upregulation of IFNg expres-
sion (Fig. 5D). Interestingly, the combined stimulation of NK cells
with IL-15 and exosomes, further enhanced IL-15 induced IFNg
production, with no differences between exosomes-derived from
Figure 4. MM cell-derived exosomes do not affect NK cell degranulation and cytotoxicity but enhance cytokine and chemokine production. (A) NK cells were incubated
for 48 h with 20 mg/mL of SKO-007(J3)-derived exosomes. The degranulation assay was performed against the sensitive target K562, using the CD107a lysosomal marker.
The percentage of CD107C NK cells is indicated in each panel. Two representative donors are shown. (B) The mean values of five independent experiments are shown.
(C) NK cells were incubated in the presence of exosomes as in panel (A). The cytotoxic activity of untreated or exosome-treated NK cells was assayed against K562 target
cells. Two representative experiments are shown. (D) The mean values of three independent experiments at the indicated E:T ratio are shown. (E) NK cells were incubated
in the presence of exosomes as in panel (A). Cells were harvested and supernatants were collected and the amount of different cytokines as indicated, was measured by
performing a Luminex assay. The mean values of three independent experiments § SEM are shown. Medium containing exosome alone has undetectable levels of cyto-
kine/chemokines (data not shown).
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untreated or MEL-treated MM cells (Figs. 5E and F). Finally, we
explored the possible effect of conditioned-media obtained from
untreated or exosome-treated NK cells, on MM cell proliferation
and survival. The rate of cell proliferation (Figs. S4A and B) and
apoptosis (Fig. S4C) was comparable in SKO-007(J3) cells cultured
with conditioned-media obtained from either control or exosome-
treated NK cells.
These data demonstrate that MM-derived exosomes can
stimulate IFNg production but not the degranulation or cyto-
toxicity of NK cells, and this event requires the activation of
NF-kB signaling pathway.
MM-derived exosomes stimulate IFNg production in a toll-
like receptor 2 (TLR2) dependent manner
It has been shown that exosomes from different cellular sources
have the capability to trigger immune cell functions through a
mechanism requiring receptors belonging to the TLR family,
namely TLR7, 8, 1 and 2.38-41 Since NF-kB activation is a major
signaling event downstream to TLRs, we asked whether exo-
some-induced NF-kB activation could be mediated by one or
more TLRs. To this aim, we used a panel of 293-derived
reporter cell lines engineered to co-express a specific TLR along
with an NF-kB-driven luciferase reporter. Interestingly, expo-
sure to exosomes induced luciferase activity only in the reporter
cell line expressing TLR2, whereas no effect was observed in
cells expressing TLR3, TLR4, TLR7, TLR8 and TLR9 (Fig. S5A)
or in cells expressing the NF-kB-driven luciferase reporter gene
alone (Fig. S5B). These data suggest that MM cell-derived exo-
somes can activate NF-kB signaling by engaging TLR2.
Since we defined an important role for TLR2, the effect of a
specific agonist on NK cell activation was promptly examined.
Thus, highly purified PB NK cells were treated with different
doses of the TLR2 agonist, Pam3CSK4 or exosomes, and IFNg
production was evaluated by immunofluorescence and FACS
analysis on both CD56high and CD56low NK cells. Interestingly,
Pam3CSK4 treatment strongly stimulated IFNg expression in
the majority of CD56high NK cells, whereas just a small percent-
age of CD56low NK cells responded to TLR2 agonist. Remark-
ably, also MM-derived exosome-induced IFNg production was
prevalent in CD56high NK cells (Figs. 6A and B). To further
prove that the CD56high NK cell subset was more responsive to
both exosomes and Pam3CSK4, CD56high and CD56low NK cell
subsets were FACS sorted based on CD56 expression levels
(Fig. 6C), and IFNg mRNA expression was evaluated upon
exosome or Pam3CSK4 treatment. As shown in Fig. 6C, in
Figure 5. MM cell-derived exosomes stimulate IFNg production through a mechanism mediated by NF-kB pathway. (A) NK cells were incubated for 48 h with 20 mg/mL
of SKO-007(J3)-derived exosomes. Real-time PCR analysis of IFNg mRNA. Data, expressed as fold change units, were normalized with b-actin and referred to the untreated
cells considered as calibrator. Values reported represent the mean of six independent experiments § SEM. (B) NK cells were incubated with 20 mg/mL of SKO-007(J3)-
derived exosomes as described in A. Western blot analysis was performed on total cell lysates using p65, phospho-p65 (p-p65) and b-actin Abs. Numbers beneath each
line represent quantification of p-p65 and p65 by densitometry normalized with b-actin. (C) NK cells were pretreated for 1 h with the NF-kB inhibitor, SN50 (15 mM), and
then incubated with 20 mg/mL of SKO-007(J3)-derived exosomes for 48 h. Real-time PCR analysis of IFNg mRNA was performed as described in panel (A). The mean of
three independent experiments is shown. (D) Nuclear extracts were prepared from NK cells untreated or treated with MM-derived exosomes, and analyzed by EMSA. The
nuclear extract derived from NK cells treated with MM exosomes was used for competition with unlabelled probes as indicated in the right panel. (E) NK cells were cul-
tured with 20 mg/mL of SKO-007(J3) cells-derived exosomes in the presence of IL-15 (50 ng/mL). After 24 h, BFA (5 mg/mL) was added and left for additional 24 h. Intra-
cellular IFNg expression was evaluated by immunofluorescence and FACS analysis. Numbers represent the percentage of IFNgC NK cells. One representative experiment
is shown. (F) Data were represented as mean values of the percentage of IFNgC cells of seven independent experiments § SEM.
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response to exosome or TLR2 agonist stimulation, upregulation
of IFNg mRNA expression was observed only in the CD56high
NK cell subset. Of note, the above differences in responsiveness
to TLR2 agonist and exosomes were not attributable to differ-
ent levels of cell surface TLR2 expressed by the two NK cell
subsets (Fig. 6D).
To further investigate the contribution of TLR2 in the exo-
some-mediated IFNg production by CD56high NK cells, an
anti-TLR2 neutralizing antibody was added to FACS-sorted
CD56high NK cells before exosome stimulation. This resulted in
a blockade of both Pam3CSK4 and exosome-mediated IFNg
production by CD56high NK cells from two different healthy
donors (Fig. 6E).
Collectively, our results indicate that (a) MM-cell derived
exosomes stimulate IFNg production by human primary NK
cells through the engagement of TLR2 and (b) the CD56high
subset is prevalently responsible for IFNg production by exo-
some-targeted NK cells.
HSP70 is associated with MM-derived exosomes and
contributes to IFNg production
A variety of DAMPs have been classified as TLR2 ligands
including Versican, HMGB1 and HSPs.13 Having detected that
lysates prepared from MM-derived exosomes displayed strong
anti-HSP70 immunoreactivity (Fig. 2C), we investigated
HSP70 localization on the outer surface of the exosome mem-
brane. To this aim, the cmHsp70.1 mAb, previously shown to
recognize cell surface HSP70,42 was used to stain exosome-bead
conjugates. Our findings show that exosomes derived from
both ARK and SKO-007(J3) MM cells displayed surface HSP70
expression. Similar levels were detected in exosomes derived
from untreated or MEL-treated cells (Fig. 7A), despite the fact
that MEL treatment upregulated cell surface HSP70 expression
in both MM cell lines (Fig. S6).
Recent evidence show that the C-terminal domain of sur-
face-exposed HSP70 can be bound by the A8 peptide aptamer,
thereby preventing HSP70/TLR2 association and the TLR2-
Figure 6. MM exosomes stimulate IFNg production in a TLR2-dependent manner. (A) NK cells were incubated with increasing doses of Pam3CSK4 or SKO-007(J3) cell-
derived exosomes, as indicated. After 24 h, BFA (5 mg/mL) was added and left for additional 24 h. Intracellular IFNg expression was evaluated by immunofluorescence
and FACS analysis. The gating strategy used consists in separating CD56high cells from CD56low NK cells. Numbers indicate the percentage of IFNgC cells. A representa-
tive experiment is shown. (B) NK cells were incubated with exosomes (20 mg/mL) as described in panel (A). The mean values of four independent experiments § SEM is
shown. (C) NK cells were FACs sorted based on CD56 expression levels, and incubated for 48 h with SKO-007(J3)-derived exosomes (20 mg/mL) or Pam3CSK4 (1 mM).
Real-time PCR analysis of IFNg mRNA was performed and the data, expressed as fold change units, were normalized with b-actin and referred to the untreated cells con-
sidered as calibrator. The mean values of five independent experiments § SEM are shown. (D) Cell surface expression of TLR2 was evaluated on CD56CCD3¡ total NK
cells, on CD56highCD3¡ and CD56lowCD3¡ NK cell subsets of total PBMC derived from 10 different healthy donors. Values represent the mean fluorescence intensity (MFI)
of TLR2 substracted from the MFI value of the isotype control Ig. (E) CD56high NK cells were pretreated for 20 min with anti-TLR2 neutralizing antibody (1mg/106 cells),
and then incubated with both TLR2 agonist and exosomes as described in panel (B). Real-time PCR analysis of IFNg mRNA was performed and the data, expressed as fold
change units, were normalized with b-actin and referred to the untreated cells considered as calibrator. Results relative to two representative donors are shown.
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dependent activation of myeloid-derived suppressor cells
(MDSCs) by tumor-derived exosomes.43
The addition of the A8 peptide to the culture medium par-
tially suppressed the induction of IFNg expression by MM cell-
derived exosomes, whereas a scrambled peptide had no effect
(Fig. 7B), indicating that HSP70 expressed on the outer mem-
brane of exosomes could contribute to TLR2 triggering in NK
cells.
Overexpression of HSP70 in cancer cells has been associated
to tumor progression and the majority of HSP70 is mainly
associated with lipid vesicles secreted by tumor cells displaying
HSP70 on their surface.44,45 We thus investigated HSP70
expression on exosomes purified from the PB and BM of MM
patients (Figs. S7A and B). Interestingly, although the levels of
CD63 were comparable in the two pools of exosome prepara-
tions, HSP70 was mainly present on BM-derived exosomes
(Figs. 7C and D). Next, we examined whether primary malig-
nant PCs could effectively contribute to the HSP70C exosome
pool in the BM, and our results show that highly purified PCs
isolated from the BM of two different MM patients had the
capability to produce HSP70C exosomes in short-term (48 h)
cultures (Fig. S7C). All together these data indicate that HSP70
is expressed on the surface of MM exosomes and contributes to
exosome-induced IFNg production by NK cells. Moreover,
exosomes expressing HSP70 are mainly found in the BM tumor
microenvironment.
Discussion
Exosomes play a relevant role in intercellular communication,
thanks to their ability to convey many proteins, lipids, miRNAs
and mRNA onto target cells.2,4 Several studies describe the
involvement of exosomes in the modulation of both innate and
adaptive immune response through different mechanisms.1,3,46
As for NK cells, the immunomodulatory role of exosomes
appears to be multi-faceted and dependent on the identity of
both the exosomes-associated cargo end exosome releasing
cells.23,47 In this context, the inhibitory action of Tex on NK
cell functions has been mostly attributed to TGF-b and/or
NKG2D ligands associated to these vesicles.24-30
Focusing on MM as a clinically and biologically relevant
model of tumor-NK cell interactions, we report herein that (i)
melphalan, a drug currently used in anti-MM chemotherapy,
enhances the release of exosomes from MM cells; (ii) MM-
derived exosomes are capable of inducing INFg production by
NK cells through a mechanism that entails activation of NF-kB
downstream to TLR2; (iii) HSP70 displayed on the outer sur-
face of MM-derived exosomes is a major trigger of TLR2
Figure 7. HSP70 is associated to MM cell-derived exosomes and contribute to IFNg production. (A) HSP70 expression on the surface of exosomes was assessed after over-
night incubation of exosomes with latex-beads. Exosomes derived from untreated or MEL-treated MM cells were stained with anti-HSP70 mAb or control isotypic Ig. One
out of three experiments is shown. (B) Purified NK cells were incubated for 24 h with 20 mg/mL of SKO-007(J3)-derived exosomes in the presence of A8 aptamer or with
a scramble peptide both used at 30 mM. Real-time PCR analysis of IFNg mRNA was performed and the data, expressed as fold change units, were normalized with b-actin
and referred to the untreated cells or scramble/treated cells considered as calibrators. The mean values of three independent experiments § SEM are shown. (C–D) Exo-
somes were extracted from the plasma of PB or BM-derived from MM patients (Pt), lysed in RIPA buffer and ELISA for HSP70 or CD63 was performed. In panel (C), absolute
values of both CD63 and HSP70 are shown for five patients. In panel (D), values of HSP70 were normalized with CD63 and used to compare the relative amount of BM
HSP70 vs. PB HSP70. Results relative to nine patients are shown.
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activation in NK cells. Hence, our study describes a novel para-
digm of drug-induced modifications in MM cells capable of
affecting tumor development through the regulation of NK cell
activity.
We initially observed that MM cell-derived exosomes had
the typical size and morphology as assessed by electron micros-
copy and DLS together with the expression analysis of some
characteristic markers as described previously.48,49 Our findings
also show that both resting or IL-15 activated primary NK cells
internalize, and not only bind MM cell-derived exosomes with
a rapid kinetics. Interestingly, we found that NK cell exosome
uptake is an active process that mainly depends on endocytic
route/s requiring dynamin and caveolae/raft endocytosis
(Fig. 3E) with TLR2 laying no apparent role (data not shown).
We provide novel evidence that the MM-derived exosomes
induced IFNg production on CD56high NK cells is mediated by
TLR2 engagement. The different response to TLR2 triggering
among CD56high and CD56low subsets was not attributable to
differences in either the levels of cell surface TLR2 expression
or to a different capability to uptake exosomes. In line with
these results, it was previously shown that IFNg production in
response to PSK2, one of the known TLR2 agonists, was mainly
associated to the NK CD56high subset.50 Thus, it is likely that
the higher responsiveness of the CD56high cell subset to exo-
some treatment mainly relies on its intrinsic ability to produce
cytokines.
Besides IFNg production, MM exosomes also induced the
expression of the CD69 activation marker and the production
of several cytokines whereas they did not affect NK cell degran-
ulation and cytotoxicity. Our data are in agreement with previ-
ous work showing that TLR engagement on NK cells can
stimulate cytokine production without affecting cytotoxicity.51-
53 Similar to our results, exposure of NK cells to TLR2 agonists
was found to allow the induction of CD69 expression as well as
the production of IFNg.54,55 Of interest, unlike other studies
reporting that different types of exosomes have the capability
to trigger immune cell functions through different receptors
belonging to TLR family, including TLR7, 8, 1 and 2,38-41 only
TLR2 is involved in the MM exosome-induced NK cell
activation.
One of the main pathway triggered by TLRs is NF-kB, a
transcription factor implicated in activation of several cytokine
genes, including IFNG.37 We found that exosome-induced
IFNg production was dependent on NF-kB signaling. Consis-
tent with these findings, a recent study has proposed a model
of TLR2-mediated NF-kB activation and consequent cytokine
production in human macrophages in response to breast cancer
cell-derived exosomes.38
TLR2 can recognize different types of DAMPs including
HSPs.56,57 In general, these molecular chaperones are usually
expressed intracellularly where they support the folding and
the transport of a great variety of proteins. In contrast, mem-
brane-bound and extracellular-located HSPs act as potent dan-
ger signals.58 Several pieces of evidence demonstrate that
extracellular-located HSPs can be associated to extracellular
vesicles.31,32,43,59 Our results show that MM exosomes
expressed high levels of HSP70 on the surface, and we also
demonstrate that this molecule contributed to exosome-
induced IFNg production by NK cells.
Notably, the presence of HSP70C exosomes primarily in the
BM of MM patients allows us to suggest that these vesicles play
a pivotal role in the tumor microenvironment by affecting
immune cell functions. In this regard, our preliminary data
indicate that CD56high NKcells are present in the BM of MM
patients suggesting that this subset might promptly respond to
HSP70/exosomes-mediated stimulation (Zingoni et al. data not
shown). In addition, other TLR2C immune cells (i.e., MDSC,
DC, etc.) resident in the MM BM microenvironment could also
be affected by the exosomes. In this regard, Chalmin and col-
leagues demonstrated that Hsp72 located on the tumor exo-
some surface was able to engage TLR2 expressed on MDSCs.39
Moreover, MM exosomes overexpressing membrane-bound
Hsp70 have the capability to induce DC maturation and stimu-
late a type 1 CD4C T and CD8C T-cell responses along with the
induction of NK cell-mediated immunity in mice.60 Thus, MM
cell-derived exosomes in vivo could affect tumor survival and
progression, thanks to their ability to regulate different subsets
of immune cells localized in the BM microenvironment and
responsive to HSP70.
Of interest, we also provide evidence that low doses of the
genotoxic agent MEL stimulate an increased release of exo-
somes from MM cells. In terms of modulatory effects on NK
cells, no differences were observed between exosomes derived
from untreated and MEL-treated cells. Moreover, since we
found a dose-dependent correlation between the exosome
amount and NK cell activation, chemotherapy could play a cru-
cial role in the induction of a stronger NK cell-mediated
immune response consequent to the enhancement of exosome
release. In this regard, TLR2 agonist treatment was proposed as
adjuvant in cancer immunotherapy,61 because it caused strong
activation of NK cells in the context of ADCC induced by the
therapeutic antibody Trastuzumab.50 Our results are in line
with recent evidence that exosome release in tumor cells was
augmented in response to different drugs, including etopo-
side,32 cisplatin and 5-fluorouracil.43
In summary, our findings add new information on the
immunomodulatory action of MM-derived exosomes during
the course of chemotherapeutic interventions. We propose a
novel mechanism whereby chemotherapeutic drugs act in syn-
ergy with antitumor innate immune response based by enhanc-
ing the release of nanovesicles exposing DAMPs, such as
HSP70. We envisage that a better characterization of exosome
molecular phenotype and immunomodulatory properties will
provide new insights into their immune-regulatory role during
chemotherapy and, possibly, into their use as prognostic
biomarkers.
Materials and methods
Antibodies and reagents
The following antibodies were from BD Biosciences (San Jose,
CA): anti-CD3/APC-H7 (clone SK7), anti-CD3/APC (clone
SK7), anti-CD56/PE (clone NCAM16.2), anti-IFNg/APC
(clone B27), anti-CD38/APC (clone HIT2), anti-CD138/FITC
(clone MI15), anti-BrdU/FITC (clone B44). Anti-CD63 (H-
193), anti-Hsp70/Hsc70 (W27), anti-CD81 (H-121), NF-kB
p65 (C-20), anti-Tsg101 (M-19) were purchased from Santa
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Cruz Biotechnology (CA). Phospho-NF-kB p65 (Ser 536)
(clone 7F1) was from Cell Signaling (Danvers, MA). Anti-calre-
ticulin was from Thermo Fisher Scientific (Rockford, USA).
Anti-MHC I (clone HC10) was kindly provided from Dr P.
Giacomini, Regina Elena Cancer Institute, Rome, Italy. Anti-
human Hsp70/FITC (clone cmHsp70.1) was provided from
Prof. Multhoff G,35 Department of Radiation Oncology, Tech-
nische Universit€at M€unchen, Munich, Germany. The following
antibodies were from BioLegend (San Diego, CA): control
mouse IgG1 (clone MOPC-21), anti-human CD69/APC (clone
FN50), anti-human CD63/PE (clone H5C6). F(ab)2 fragments
of APC conjugated goat-anti-mouse (GAM-APC or GAM-PE)
IgG were from Jackson Immunoresearch Laboratories (West
Grove, PA). Anti-b-actin (clone AC-74, IgG2a) was from
Sigma-Aldrich (St Louis, MO); anti-hTLR2-IgA neutralizing
antiboby (clone B4H2) was from InvivoGen (San Diego, CA);
anti-human CD282 (TLR2) APC (clone TL2.1) and Annexin V
apoptosis detection kit were from eBioscience (California,
USA). The NF-kB SN50 inhibitor peptide was from Calbio-
chem (Los Angeles, USA). Other reagents used were as follows:
bovine serum albumin (BSA), brefeldin A (BFA), saponin,
paraformaldehyde (PFA), propidium iodide (PI), trypan blue,
dimethylformamide (DMF), puromycin, Melphalan, dynasore,
nystatin, 5-(N-ethyl-N-isopropyl) amiloride (EIPA), all from
Sigma-Aldrich (St Louis, MO). In addition, hygromycin, blasti-
cidin, R848, Pam3CSK4, ODN 2216, Poly (I:C), LPS were from
InvivoGen (San Diego, CA). Recombinant Human IL-15 was
purchased from Peprotech (Rocky Hill, NJ). The peptide
aptamer A8 (SPWPRPTY)62 and the scramble (TPWYPSRP)
were synthesized and highly purified by BioFab Research (Italy,
Rome).
Cells and culture conditions
The human MM cell lines SKO-007(J3) and ARK, were pro-
vided by P. Trivedi (“Sapienza” University of Rome). The cell
lines were maintained at 37C and 5% CO2 in RPMI 1640 (Life
Technologies, Gaithersburg, MD) supplemented with 10% FBS.
Primary human foreskin fibroblasts (HFFs) were purchased
from the American Type Culture Collection and were grown in
DMEM supplemented with 10% FBS. All cell lines were myco-
plasma free (EZ-PCR Mycoplasma test kit; Biological
Industries).
Patients
Clinical samples from patients with MM were managed at the
Division of Hematology (“Sapienza” University of Rome).
Informed consent, in accordance with the Declaration of Hel-
sinki, was obtained from all patients, and approval was
obtained from the Ethics Committee of “Sapienza” University
of Rome. The BM aspirates were processed, as described previ-
ously.19,22 In some experiments, myeloma cells were purified
using anti-CD138 magnetic beads (Miltenyi Biotec, Auburn,
CA).19,22 More than 95% of the purified cells expressed CD138
and CD38.
Exosome purification
Exosome-free medium was obtained as follows: FBS was centri-
fuged at 100,000 g for 3 h in a Beckman ultracentrifuge (Beck-
man Coulter, Brea, CA) to remove microvesicles-like
exosomes. RPMI 1640 was supplemented with 10% of FBS-exo-
some free and antibiotics. ARK and SKO-007(J3) cell lines were
cultured at 0.8–1£106 cells/mL in exosome-free medium for
48 h. In some experiments, cells were treated with a sublethal
dose of Melphalan (MEL) determined by the MTT assay and
was 3mM for ARK and 5mM for SKO-007(J3). Exosome purifi-
cation protocol consists of different sequential centrifugations
as previously reported.35 In some experiments, HFFs were
grown for 5 d up to reach confluence and the conditioned
medium was used to isolate exosomes. PBMCs were plated at
3£106 cells/mL for 48 h and the conditioned medium was used
to isolate exosomes. Briefly, cells were harvested by centrifuga-
tion at 300 g for 10 min and supernatants were collected. Cell-
free supernatants were then centrifuged at 2,000 g for 20 min
followed by centrifugation at 10,000 g for 30 min to remove
cells and debris. Supernatants were filtered using a 0.22 mm fil-
ter and centrifuged at 100,000 g for 70 min at 4C in a Beckman
ultracentrifuge to pellet exosomes. The resulting pellet was
washed in a large volume of cold PBS and again centrifuged at
100,000 g for 70 min at 4C. Finally, exosomes were resus-
pended in PBS for further analyses and functional studies.
MM patients plasma was collected from BM aspirates and
from PB by centrifugation at 400 g for 10 min, stored at ¡80C
and further used for exosome extraction. One mL of MM
patient plasma was centrifuged at 2,000 g for 30 min, superna-
tants were collected and 0.2 volumes of the Total Exosome Iso-
lation reagent (Invitrogen) were added. The samples were
incubated for 30 min at 4C followed by centrifugation at
10,000 g for 10 min at RT. The pellet was resuspended in PBS,
filtered using a 0.22 mm filter and washed two times by centri-
fugation at 100,000 g for 70 min at 4C. Finally, exosomes were
resuspended in PBS.
Size experiments through DLS
DLS experiments were performed to measure exosome size and
concentration. All themeasurements weremade at 25C on a Zeta-
sizer Nano ZS90 spectrometer (Malvern, UK) equipped with a
5 mW HeNe laser (wavelength λ D 632.8 nm) and a non-invasive
back-scattering optical setup (NIBS). For each sample, the detected
intensity was processed by a digital logarithmic correlator, which
computes a normalized intensity autocorrelation functions. Then,
the distribution of the diffusion coefficient Dwas obtained by using
the CONTIN method.63 D was converted into an effective hydro-
dynamic diameter DH through the Stokes–Einstein equation: DH
D KBT/(3phD), where KBT is the system’s thermal energy and h
represents the solvent viscosity. Solvent-resistant micro cuvettes
(ZEN0040, Malvern, Herrenberg, Germany) have been used for
experiments with a sample volume of 40 mL. The count rates
obtained were then corrected for the attenuator used. Results are
given asmean§ standard deviation of five replicates. Exosome size
distribution and concentration were calculated by a recently pro-
posed DLS-based non-invasive tool. More details can be found in
the supplementarymethodology and in Fig. S1.64,65
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Ultrastructural analysis and immunoelectron microscopy
Transmission electron microscopy (TEM) of MM cells-isolated
exosomes was performed as follow. Briefly, exosomes were
fixed in 2% PFA and adsorbed on formvar-carbon-coated cop-
per grids. The grids were then incubated in 1% glutaraldehyde
for 5 min, washed with deionized water eight times, and then
negatively stained with 2% uranyl oxalate (pH 7) for 5 min and
methyl cellulose/uranyl for 10 min at 4C. Excess methyl cellu-
lose/uranyl was blotted off, and the grids were air-dried and
observed with a TEM (Philips Morgagni268D) at an accelerat-
ing voltage of 80 kV. Digital images were taken with Mega
View imaging software. For immunoelectron microscopy, exo-
somes were fixed in 2% PFA and adsorbed on formvar-carbon-
coated nickel grids. The grids were then incubated with pri-
mary antibodies anti-TSG101 and anti-CD81 overnight. After
several washes with PBS the grids were then incubated with
specific secondary antibodies conjugated with colloidal gold
(Sigma Aldrich, Milan, Italy). The grids were then washed in
PBS, fixed in 1% glutaraldehyde, washed with deionized water,
and then negatively stained with 2% uranyl oxalate (pH 7) and
methyl cellulose/uranyl as described previously. The grids were
air-dried and observed with a TEM (Philips Morgagni268D) at
an accelerating voltage of 80 kV. Digital images were taken
with Mega View imaging software.
Liposome preparation
The zwitterionic lipid 1,2-dimyristoyl-sn-glycero-3-phospho-
choline (DMPC) and cholesterol (Chol) were purchased from
Avanti Polar Lipids (AL, USA) and used without further purifi-
cation. DMPC:Chol (4:1 molar ratio) liposomes were routinely
prepared. In brief, a lipid mixture was dissolved in chloroform
and then let to evaporate under vacuum for 24 h. The obtained
lipid film was hydrated with PBS (final lipid concentration D 1
mg/mL). The obtained liposome solutions were extruded
20 times through a 0.1 mm polycarbonate carbonate filter with
the Avanti Mini-Extruder (Avanti Polar Lipids, AL, USA).
Flow cytometry analysis of exosomes
FACS analysis of CD63C exosomes was performed by positive
magnetic selection using CD63C dynabeads (Invitrogen).
About 5–10 mg of exosomes were incubated with 20 mL of
magnetic beads for 18–22 h at 4C with gentle tilting. The
bead-bound exosomes were labeled with cIg/PE or anti-CD63/
PE (BioLegend). In other experiments, Aldehyde/Sulfate Latex
Beads (Thermo Scientific) were incubated 18-22 h with about
2–4 mg of exosomes. The bead-bound exosomes were incu-
bated with 100 mM of glycine for 30 min at RT, then washed
three times and labeled with cIg/FITC (BioLegend) or anti-
Hsp70/FITC (clone cmHsp70.1). Samples were acquired using
a FACSCanto (BD Biosciences, San Jose, CA) and data analysis
was performed using the FlowJo program.
RNA isolation, RT-PCR and real-time PCR
Total RNA from human primary purified NK cells was
extracted using Total RNA Mini Kit (Geneaid, New Taipei
City, Taiwan). Total RNA (100 ng–1 mg) was used for cDNA
first-strand synthesis using oligo-dT (Promega, Madison, WI)
in a 25 mL reaction volume. Real-time PCR was performed
using the ABI Prism 7900 Sequence Detection system (Applied
Biosystems, Foster City, CA). cDNAs were amplified in tripli-
cate with primers for IFNg (Hs00989291_m1), and human
b-actin (Hs99999903_m1), all conjugated with fluorochrome
FAM (Applied Biosystems). The cycling conditions were: 50C
for 10 min, followed by 40 cycles of 95C for 30 sec, and 60C
for 2 min. Data were analyzed using the Sequence Detector
v1.7 analysis software (Applied Biosystems). The level of gene
expression was measured using threshold cycle (Ct). The Ct
was obtained by subtracting the Ct value of the gene of interest
from the housekeeping gene (b-actin) Ct value. In the current
study, we used Ct of the untreated sample as the calibrator. The
fold change was calculated according to equation 2¡DDCt, where
DDCt was the difference between Ct of the sample and the Ct of
the calibrator (according to the formula, the value of the cali-
brator in each run is 1).
SDS-PAGE and Western blot analysis
For Western blot analysis, SKO-007(J3) or ARK cells or exoso-
mal preparations were lysed in 1X RIPA lysis buffer (1% NP-
40, 0.1% SDS 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5%
Sodium Deoxycholate, 1 mM EDTA) plus complete protease
inhibitor mixture and phosphatase inhibitors as described pre-
viously.66 Protein concentration was determined with the Bio-
Rad Protein Assay (BPA). 40 to 50 mg of cell or exosome
extract was run on 8% or 10% denaturing sodium dodecyl sul-
fate (SDS)-polyacrylamide gels. Proteins were then electro-blot-
ted onto nitrocellulose membranes (Schleicher & Schuell,
Keene, NJ) and blocked in 5% milk in TBST buffer for 1 h.
Immunoreactive bands were visualized on the nitrocellulose
membranes, using Horseradish Peroxidase (HRP)-coupled goat
anti-rabbit or goat anti-mouse Igs and the enhanced chemilu-
minescence kit (ECL) detection system (GE Healthcare Amer-
sham), following the manufacturer’s instructions.
Electrophoretic mobility-shift assay (EMSA)
Nuclear proteins were prepared as described previously.67 Pro-
tein concentration of extracts was determined by the BPA
method (Pierce, Rockford, IL). The nuclear proteins (4 mg)
were incubated with radiolabeled DNA probes in a 20 mL reac-
tion mixture containing 20 mM Tris (pH 7.5), 60 mM KCl,
2 mM EDTA, 0.5 mM dithiothreitol (DTT), 1 mg of poly(dI-
dC) and 4% ficoll. Where indicated, a molar excess of double-
strand oligomer was added as a cold competitor and the mix-
ture was incubated at room temperature for 10 min before add-
ing the DNA probe. Nucleoprotein complexes were resolved as
described previously.67 Oligonucleotides were purchased by
BioFab (Rome, Italy). Complementary strands were annealed
and end-labeled as described.67 Approximately 3£104 cpm of
labeled DNA was used in a standard electrophoretic mobility-
shift assay reaction. The following double-strand oligomers
were used as specific labeled probes or cold competitors (sense
strand): Octamer-(h-Histone H2b), 50-agctcttcaccttatttgca-
taagcgat-30 and the oligo containing an NF-kB binding site
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C3–3P (¡278 to ¡268) of the IFNG promoter 50-gggaggta-
caaaaaaatttccagtccttga-30.37
Human NK cell isolation
Highly purified primary NK cells were obtained from human
peripheral blood mononuclear cells (PBMCs) by negative selec-
tion using magnetic beads (Miltenyi Biotec). NK cell purity was
more than 96% CD56CCD3¡ as assessed by immunofluores-
cence and flow cytometry analysis (data not shown). In some
experiments, NK cells were sorted based on CD56 expression
levels for high and low NK cells using a BD FACSAria III (BD
Biosciences) equipped with FACSDiva software (BD Bioscien-
ces version 6.1.3) as shown in Fig. 6C.
Intracellular cytokine production, degranulation assay,
51Cr-release assay and cell proliferation
For intracellular cytokine detection, NK cells were seeded at 2–
3£106/mL in exosome-free medium, and incubated with differ-
ent doses of MM cell-derived exosomes (1–20 mg/mL) for 24 h.
BFA was added at 5 mg/mL and left for additional 24 h. In
some experiments, NK cells were treated with recombinant
human IL-15 (50 ng/mL) and sometimes, before exosomes
exposure, NK cells were pre-incubated with the NF-kB peptide
inhibitor SN50 (15 mM) for 1 h at 37C. Degranulation assay
was performed as described previously.22 The 51Cr-release assay
was used to measure cytotoxic activity against K562 target cells,
as described previously.68 Cell proliferation of SKO-007(J3)
cells was evaluated as follow: BrdU (20 mM) was added to the
culture for 7 h, cells were harvested, fixed in a solution contain-
ing 30% methanol, 4% PFA. After washing with PBS, cells were
incubated at ¡20C for at least 18 h. Cells were permealized
with a solution containing 1% Tween-20 and treated with
DNAse (0.250 mg/mL) for 15 min at RT. After washing, cells
were stained with anti-BrdU/FITC or with a control Ig-FITC.
Immunofluorescence and FACS analysis
For intracellular cytokine detection, human primary NK cells
were first labeled with anti-CD56/PE and then PBS washed and
fixed in 1% PFA for 20 min at room temperature (RT). After
washing, cells were incubated with PBS containing 2% BSA for
15 min at RT and then permeabilized with PBS containing
0.5% saponin and 1% FBS for 20 min at RT. After washing, cells
were labeled with anti-IFNg/APC. In other experiments, NK
cells were stained with anti-CD69/APC or TLR2/APC together
with antiCD56/PE and CD3/APCH7. All the samples were
acquired using a FACSCanto (BD Biosciences, San Jose, CA)
and data analysis was performed using the FlowJo program.
Exosome uptake
100 mg of exosomes diluted in PBS were incubated with the red
fluorescent dye PKH26 (Sigma-Aldrich). Exosomes were
washed twice with PBS by centrifugation at 100,000 g for 1 h.
PKH26-labeled exosomes were diluted with PBS and used for
uptake experiments. Primary NK cells were plated on poly-L-
lysine-coated multichamber glass plates in complete medium
and incubated with PKH26-labeled exosomes (20 mg/mL) for
different times. Medium was removed and the cell monolayer
was gently washed with PBS, and fixed with 4% PFA. Cover-
slips were mounted using SlowFade Gold reagent (Life Tech-
nologies) and acquired at room temperature using an
ApoTome Observer Z.1 microscope with an Axiocam MR
equipped with AxioVision Version 4.6.3 software for image
acquisition as described previously.69 In some experiments,
PKH26-labeled exosomes were incubated with highly purified
NK cells for different times. Cells were collected, washed twice
with PBS and then samples were acquired using a FACSCanto
(BD Biosciences, San Jose, CA). Data analysis was performed
using the FlowJo program.
ELISA/Luminex
Detection of Hsp70 or CD63 in total exosomes lysates was per-
formed using specific ELISA kits from R&D Systems (DY1663–
2) and BioSource (MBS763944), respectively. Plates were devel-
oped using a peroxidase substrate system (R&D Systems), and
then read with the Victor3 multilabel plate reader (Model #
1420–033, Perkin Elmer, Santa Clara, CA) capable of measur-
ing absorbance in 96-well plates using dual wavelength of 450–
540 nm. Results were expressed as picograms per milliliter (pg/
mL) and referred to a standard curve obtained by plotting the
mean absorbance for each standard on the y-axis against the
concentration on the x-axis and drawing a best-fit curve
through the points on the graph. Detection of cytokines and
chemokines (i.e., IFNg, CXCL8/IL-8, CCL5/Rantes, CCL4/
MIP1b, CX3CL1/fractalkine, CXCL10/IP-10) in the same
supernatants was performed with a Milliplex MAP Human
Cytokine/Chemokine Magnetic Bead Panel—Immunology
Multiplex Assay according to the manufacturer’s instructions
(Millipore). Plates were read with Bio-Plex MAGPIX Multiplex
Reader (BIO-RAD).
NF-kB luciferase reporter assay
TLR-specific activation assays were performed using human
embryonic kidney 293 (HEK293) cells expressing luciferase
under control of the NF-kB promoter and stably transfected
with either TLR4, MD2, and CD14 (TLR4-HEK293), TLR2
(TLR2-HEK293), TLR3 (TLR3-HEK293), TLR7 (TLR7-
HEK293), TLR8 (TLR8-HEK293) and TLR9 (TLR9-HEK293).
HEK293-transfected cells were maintained in DMEM supple-
mented with 4.5 g/L glucose and 10% FBS, 1% penicillin/strep-
tomycin solution (Invitrogen), and specific antibiotics for the
different cell lines were added. All the HEK293-transfected cells
were kindly provided by Dr U. D’Oro (GlaxoSmithKline Vac-
cines, Siena). For the NF-kB luciferase assay, 30,000 cells/well
were seeded in 100 mL of complete DMEM without antibiotics
in 96-well plates and incubated for 18 h at 37C. Different con-
centrations of exosomes (1–20 mg/mL) were added and left for
different times (2–18 h). As positive control for each transfec-
tant, specific TLR agonists were used as follow: TRL2
(Pam3CSK4, 1 mM), TLR3 (Poly(I:C), 1 mg/mL), TLR4 (LPS,
10 mg/mL), TLR7 and TLR8 (R848, 10 mM), TLR9 (CpG,
50 mM). After incubation, supernatants were aspired from each
well, cells were washed with PBS and then were lysed for
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15 min at room temperature using 100 mL/well of 1:5 diluted
“passive lysis buffer” (Promega, Madison WI). Protein concen-
tration was evaluated by BPA. 3 mg of total proteins for each
sample were diluted in 50 mL of PBS and 50 mL of luciferase
assay substrate (Promega, Madison WI) was added. Emitted
light was immediately quantified using a luminometer Glo-
Max-Multi Detection System (Promega, Madison WI).
Statistics
Error bars represent SD or where indicated SEM. Statistical
analysis was performed with the Student paired test; p < 0.05,
p < 0.01, p < 0.001.
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